CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

Inclusion criteria: * B-cell acute lymphoblastic leukemia: refractory to two cycles of chemotherapy, relapsed after chemotherapy, or hematopoietic stem cell transplantation. * B-cell non-Hodgkin lymphoma: refractory to two lines of chemotherapy, relapsed after chemotherapy, or hematopoietic stem cell transplantation. * Age: From 1 to 60 years old (both males and females) * Adequate organ functions: * Serum creatinine ≤ 1.5 x ULN or eGFR ≥ 60 mL/min/1.73 m2 * ALT and AST ≤ 5 x ULN; Bilirubin ≤ 2.0 mg/dl * No chronic lung diseases, such as obstructive pulmonary disease or bronchial asthma, required continuous medications without respiratory failure (SpO2 oxygen saturation \> 92% at room temperature). * No arrhythmia, no intracardiac thrombus or vascular wall, no heart failure, LVEF ≥ 45% * Blood test: * Absolute neutrophil count (ANC) ≥ 1,000/mm3 (1 G/l) without filgrastim * Absolute lymphocyte count ≥ 100/mm3 (0.1 G/l) * Absolute platelet count ≥ 75,000/mm3 (75 G/l) * Hemoglobin ≥ 8.0 g/dl * Positive for CD19 measured by immunohistochemistry or flow cytometry. * Agree to participate in the study * Agree to use safe methods of contraception for female patients. Exclusion criteria: * Involved central nervous system invasion at the time of screening. * Medical history of veno-occlusive disease (VOD). * Required acute treatment due to tumors such as intestinal obstructions, vascular compression, or respiratory failure. * Having active hemolytic anemia. * Diagn…